Literature DB >> 11371746

Classification of demyelinating diseases at the interface between etiology and pathogenesis.

H Lassmann.   

Abstract

The classical demyelinating diseases include the 'autoimmune' inflammatory demyelinating diseases, the inflammatory demyelinating diseases of infectious aetiology, and the demyelinating or dysmyelinating diseases of genetic/hereditary background. In addition, primary demyelination is present in other conditions, such as brain ischaemia and intoxication. Irrespective of the primary aetiology, selective demyelination can be mediated through various pathogenetic pathways: the immune-mediated inflammatory pathway; the metabolic pathway; and the ischaemic/excitotoxic pathway. These pathways are only partly segregated with distinct aetiologies of demyelinating diseases, but they also reflect the way in which the patient copes with the disease-inciting event in relation to their particular genetic background. For future therapeutic strategies it will be important to interfere with the specific pathogenetic pathways of demyelination, which may be common to various demyelinating diseases, but may differ in subgroups of patients who suffer from a particular clinical demyelinating disease entity.

Entities:  

Mesh:

Year:  2001        PMID: 11371746     DOI: 10.1097/00019052-200106000-00001

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  18 in total

Review 1.  Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2012-06-05       Impact factor: 3.969

2.  Diverse Chemical Scaffolds Enhance Oligodendrocyte Formation by Inhibiting CYP51, TM7SF2, or EBP.

Authors:  Dharmaraja Allimuthu; Zita Hubler; Fadi J Najm; Hong Tang; Ilya Bederman; William Seibel; Paul J Tesar; Drew J Adams
Journal:  Cell Chem Biol       Date:  2019-02-14       Impact factor: 8.116

3.  Vaccine-like controlled-release delivery of an immunomodulating peptide to treat experimental autoimmune encephalomyelitis.

Authors:  Barlas Büyüktimkin; Qun Wang; Paul Kiptoo; John M Stewart; Cory Berkland; Teruna J Siahaan
Journal:  Mol Pharm       Date:  2012-03-13       Impact factor: 4.939

4.  Suppression of EAE and prevention of blood-brain barrier breakdown after vaccination with novel bifunctional peptide inhibitor.

Authors:  Ahmed H Badawi; Paul Kiptoo; Wen-Tung Wang; In-Young Choi; Phil Lee; Charlotte M Vines; Teruna J Siahaan
Journal:  Neuropharmacology       Date:  2011-12-17       Impact factor: 5.250

Review 5.  Peptides and peptidomimetics as immunomodulators.

Authors:  Ameya S Gokhale; Seetharama Satyanarayanajois
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

6.  Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.

Authors:  Alberto Spalice; Pasquale Parisi; Laura Papetti; Francesco Nicita; Fabiana Ursitti; Francesca Del Balzo; Enrico Properzi; Alberto Verrotti; Martino Ruggieri; Paola Iannetti
Journal:  Curr Neuropharmacol       Date:  2010-06       Impact factor: 7.363

7.  Controlling immune response and demyelination using highly potent bifunctional peptide inhibitors in the suppression of experimental autoimmune encephalomyelitis.

Authors:  P Kiptoo; B Büyüktimkin; A H Badawi; J Stewart; R Ridwan; T J Siahaan
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

8.  Suppression of MOG- and PLP-induced experimental autoimmune encephalomyelitis using a novel multivalent bifunctional peptide inhibitor.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  J Neuroimmunol       Date:  2013-08-01       Impact factor: 3.478

9.  Monitoring demyelination and remyelination by magnetization transfer imaging in the mouse brain at 9.4 T.

Authors:  Wafaa Zaaraoui; Mathilde Deloire; Michel Merle; Céline Girard; Gérard Raffard; Marc Biran; Matilde Inglese; Klaus G Petry; Oded Gonen; Bruno Brochet; Jean-Michel Franconi; Vincent Dousset
Journal:  MAGMA       Date:  2008-09-09       Impact factor: 2.310

10.  Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair.

Authors:  Silva Markovic-Plese; Avtar K Singh; Inderjit Singh
Journal:  Future Neurol       Date:  2008-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.